Treatment of multiple myeloma with selinexor: a review-Reference-Cited by-同舟云学术

Treatment of multiple myeloma with selinexor: a review

Published:2024-01 Issue: Volume:15 Page:
ISSN:2040-6207
Container-title:Therapeutic Advances in Hematology
language:en
Short-container-title:Therapeutic Advances in Hematology

Author:

Huang Qianlei¹^ORCID,Zhao Ranran²,Xu Lu¹,Hao Xinbao¹,Tao Shi³

Affiliation:

1. Department of Hematology, The First Affiliated Hospital of Hainan Medical University, Hainan Province Clinical Medical Center, Haikou, China

2. Department of Hematology, The Second Affiliated Hospital of Xuzhou Medical University, Xuzhou, China

3. Department of Hematology, The First Affiliated Hospital of Hainan Medical University, Hainan Province Clinical Medical Center, 31 Longhua Road, Haikou 570102, China

Abstract

Over the last 20 years, breakthroughs in accessible therapies for the treatment of multiple myeloma (MM) have been made. Nevertheless, patients with MM resistant to immunomodulatory drugs, proteasome inhibitors, and anti-CD38 monoclonal antibodies have a very poor outcome. Therefore, it is necessary to explore new drugs for the treatment of MM. This review summarizes the mechanism of action of selinexor, relevant primary clinical trials, and recent developments in both patients with relapsed/refractory myeloma and patients with newly diagnosed myeloma. Selinexor may be useful for the treatment of refractory MM.

Funder

National College Students Innovation and Entrepreneurship Training Program

Publisher

SAGE Publications

Link

http://journals.sagepub.com/doi/pdf/10.1177/20406207231219442

Reference102 articles.

1. Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma

2. Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma